asia pacific epinephrine Market

Asia Pacific, the epinephrine market, is anticipated to reach US$ 953.08 Mn in 2027 from US$ 486.79 Mn in 2019. The market is projected to grow with a CAGR of 8.9% from 2020-2027.

The epinephrine market is growing primarily due to increasing production of generic epinephrine and cheaper epinephrine products and government regulations in the Asia Pacific region that are boosting the market over the years. Restraining factors, such lack of availability of epinephrine drug, are likely to damage the growth of the market in the coming years. On the other hand, growing R&D expenditure for growing pipeline of epinephrine is expected to have a positive impact on the growth of the epinephrine market in the Asia Pacific coming years.

Anaphylaxis is a severe, life?threatening allergic reaction characterized by symptoms such as skin redness and itching, swallowing and breathing difficulties, wheezing, rapid breathing rate (tachypnoea), accelerated heart rate (tachycardia), and falling blood pressure. It may involve multiple systems of human body. Anaphylaxis is caused by exposure to an allergen (foods, insect stings, or medicines) that is recognized as a non-self by a human body.

The incidence of anaphylaxis is increasing, more than 1 billion people in the world suffered from respiratory diseases in 2018, asthma to which is a major contributor, according to the World Health Organization (WHO). The top 3 countries for both asthma incidence and prevalence in Asia were India, China, and Indonesia, driven largely by population size nearly half (48%) of estimated O3-attributable and over half (56%) of asthma emergency room visits were estimated in Southeast Asia (includes India), and western Pacific regions (includes China). Global burden of disease data analysis revealed more than one million premature deaths attributable to ambient air pollution in 2015 in India. More than one million additional deaths can be attributed to household air pollution. The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) plans to build a consortium and calls to action for the health and environmental global bodies and national authorities to address this major threat to human health. Anaphylaxis requires immediate medical treatment, and it can turn lethal if not treated properly. Therefore, the demand for epinephrine is expected to increase during the forecast period.

In 2019, the auto-injectors accounted for the largest market share in the Asia Pacific epinephrine market. Epinephrine auto-injectors are measured dosages and are also used to treat life-threatening allergic reactions. The epinephrine auto-injectors can be self-administered. The auto-injectors segment is also estimated to mark the highest CAGR in the market during the forecast period, owing to the increasing technological development that is enabling the alternative treatment of anaphylaxis by the various generic drugs.

In 2019, the anaphylaxis segment, held the most significant market share of the epinephrine market by the application. This segment is also anticipated to hold a considerable portion of the market in 2027, owing to the need for treatment of anaphylaxis and other allergies for the people. The segment is also anticipated to witness growth at a significant rate during the forecast period.
Some of the significant primary and secondary sources for epinephrine included in the report are World Health Organization (WHO), Food and Drug Administration (FDA), Food Allergy Research & Education, Centers for Disease Control and Prevention (CDC), and Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI)